Vaccine for lowering cholesterol, and triglycerides levels: Repurposing the CTB-UE vaccine into a cholesterol-lowering vaccine that inhibits Non-alcoholic fatty liver disease (NAFLD): CTB-UE vaccine, which protects against H.Pylori infection, decreases the levels of HMGCR,  triglycerides, free cholesterol, and total cholesterol and prevents the progression of Non-alcoholic fatty liver disease (NAFLD, via down regulation of its target gene, 1/August/2018, 3.16 pm

Bacillus Calmette Guerin (BCG)/tuberculosis (TB) vaccine aids in the treatment of Deafness: BCG/TB vaccine increases the expression of ATG5 (Autophagy-related 5), prevents aggregation of proteins in inclusion bodies, inhibits hair cell degeneration,  improves hearing loss via upregulation of its target genes, 1/August/2018, 2.10 pm
August 1, 2018
Awakening the sleeping/cancer-protecting angels in mutant p53-expressing human tumors: Emodin, isolated from Rhubarb and others,  increases the expression of tumor suppressors genes, such as  BigH3, TIPE2, TA-p73, TAp63, p53, and others, induces regression of p53-mutated human tumors, via down-regulation of its target gene, 1/August/2018, 3.21 pm
August 1, 2018
Show all

Significance of the study:

Given that: (1)  15-30% of Western populations suffer from Non-alcoholic fatty liver disease (NAFLD), while 6-25% of Asian populations suffer from it; (2) 75 to 100 million people in the US succumb to this disease; (3) obesity and type 2 diabetes are risk factor for the development of NAFLD;  and (4) the global economic cost spent for NAFLD is enormous, there is an urgent need to find: (i) a way to decrease cholesterol deposition in liver; (ii) a cheaper alternative to the existing expensive drugs; (iii) a side-effect-free natural product-based drug; and (iv) a way to cure, not just treat, NAFLD.


Research findings to Therapeutic opportunity:

This study suggests, first the first time, Helicobacter Pyroli vaccine CTB-UE-based therapy, with detailed mechanistic insights, for lowering cholesterol and triglyceride levels.

CTB-UE vaccine, which contains mucosal adjuvant cholera toxin B subunit (CTB) and five cell epitopes from the H. pylori urease subunits,, has been shown to be effective in controlling infections caused by H. pylori. However, the mechanism of action remains largely unknown.

CTB-UE vaccine, by increasing the expression of its target gene, it may suppress the expression of HMGCR (Fig.1). Thereby, it may: (1) decrease Triglycerides, free cholesterol and total cholesterol levels; (2) attenuate lipid deposition in the liver; and (3) inhibit progression to NAFLD (Fig. 1). Thus, CTB-UE vaccine, either alone or in combination with other drugsmay be used to treat NAFLD.

Figure 1. Mechanistic insights into how  CTB-UE vaccine decreases the expression of HMGCR, lowers cholesterol levels, decreases triglyceride levels, and NAFLD.

Figure 2. Repurposing CTB-UE vaccine into a cholesterol-lowering vaccine. CTB-UE vaccine lowers cholesterol and triglyceride levels and attenuates NAFLD through down-regulation of HMGCR

[easy_payment currency=”USD”]

 

 

 

 

 

 

 

 


Details of the research findings:

Idea Proposed/Formulated (with experimental evidence) by:

Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed mechanistic information: How does CTB-UE vaccine decrease the expression of HMGCR and prevent NAFLD?

Amount: $750#

# Research cooperation

For purchase and payment details, you may reach us at info@genomediscovery.org

* Research cooperation


References:

Web: http://genomediscovery.org or http://newbioideas.com

Citation: Boominathan, L.,Vaccine for lowering cholesterol, and triglycerides levels: Repurposing the CTB-UE vaccine into a cholesterol-lowering vaccine that inhibits Non-alcoholic fatty liver disease (NAFLD): CTB-UE vaccine, which protects against H.Pylori infection, decreases the levels of HMGCR,  triglycerides, free cholesterol, and total cholesterol and prevents the progression of Non-alcoholic fatty liver disease (NAFLD, via down-regulation of its target gene, 1/August/2018, 3.15 pm, Genome-2-BioMedicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite, drop us a line at info@genomediscovery.org

Comments are closed.